Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Gene Expression Profiling 11Surveys and Questionnaires 9Polymerase Chain Reaction 9Immunohistochemistry 9Amplified Fragment Length Polymorphism Analysis 9Flow Cytometry 8Psychiatric Rehabilitation 7Microarray Analysis 6Rituximab 5Interviews as Topic 4Cytogenetic Analysis 4Blood Specimen Collection 4Biopsy 4Therapeutics 3Immunologic Techniques 3Gene Rearrangement 3Drug Therapy 3Doxorubicin 3Data Collection 3Cyclophosphamide 3plerixafor 2Vincristine 2Prednisone 2Positron-Emission Tomography 2Phlebotomy 2Pharmacogenomic Testing 2Observation 2Neuropsychological Tests 2Mental Status and Dementia Tests 2Magnetic Resonance Spectroscopy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Lymphoma × Glycopeptides × Clear all
NCT00195533 2009-11-16

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
801 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡